Illumina Awarded $26.7M in Patent Suit Against Ariosa Diagnostics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Jan. 26, 2018-- Illumina, Inc. (NASDAQ: ILMN) announced today that a federal jury in San Francisco has ruled in its favor in a patent infringement suit filed against Ariosa Diagnostics, Inc., now owned by Roche.

The jury found that both Ariosa’s previous and current version of the Harmony non-invasive prenatal test (NIPT) infringe US Patent 8,318,430 and US Patent 7,955,794. The jury awarded Illumina approximately $26.7 million for past damages.

The jury rejected counterclaims by Ariosa that Illumina had breached a supply agreement between the companies by bringing the lawsuit.

The US Patent and Trademark Office previously upheld the validity of the patents rejecting multiple challenges filed by Ariosa.

“We are pleased with the outcome reached by the jury,” said Charles Dadswell, Senior Vice President and General Counsel for Illumina. “This verdict again validates these patents, the hard work and ingenuity of the inventors, and their significant contribution to the field of NIPT.”

Illumina intends to seek injunctive relief for ongoing infringement by Ariosa’s continuing sale of its Harmony test.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180126005640/en/

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Jacquie Ross, CFA
858-255-5243
IR@illumina.com
or
Media:
Eric Endicott
858-882-6822
pr@illumina.com